Advocacy intelligence hub — real-time data for patient organizations
Arikayce: FDA approved
Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Mendelian susceptibility to mycobacterial diseases news →
Paul Szabolcs, MD
UPMC Children's Hospital of Pittsburgh
📍 Pittsburgh, Pennsylvania
Kosuke Noma
Hiroshima University
Miyuki Tsumura
Hiroshima University
Satoshi Okada
Hiroshima University
Fereshteh Khalili-Moghaddam
Legal Medicine Research Center
Majid Zaki-Dizaji
Legal Medicine Research Center
View all Mendelian susceptibility to mycobacterial diseases specialists →